| Developers: | Stryker Corporation |
| Date of the premiere of the system: | September 2021 |
| Branches: | Pharmaceuticals, medicine, healthcare |
2021: Announcement of tendon fixation system with resorbable components
On September 15, 2021, Stryker announced that its traumatology and limb division had launched a system of tendon fixation devices called Citrelock.
According to the press release, the Citrelock system offers surgeons a differentiated tendon thread design with Citregen resorbable technology, which in turn has rare chemical and mechanical properties for orthopedic surgical applications.
Citrelock has a controlled and homogeneous resorption process designed to prevent volumetric degradation and chronic inflammation, while providing a strength comparable to cortical bone and a modulus comparable to canceled bone.
Citregen contains molecules of citrate, calcium and phosphate inherent in bone anatomy. The platform includes a polymeric material structure designed to mimic the protein network of the extracellular matrix. Citregen retains its structural integrity during the healing stage, when the implant is replaced with host tissues over time.
Stryker plans to debut with the Citrelock platform at the annual meeting of the American Orthopedic Foot and Ankle Society on September 20-26, 2021.
 | Our customers are looking for a more predictable and efficient bioresorbable material than what is now on the market. Citrelock's tendon fixation system helps meet this need with innovative material technology and unique design, said Michael Rankin, Stryker's vice president of marketing and medical education, in a release. |  |
Citregen is an interesting addition to Stryker's existing biomaterials portfolio and further expansion of the platform is planned for use in additional indications of injuries and limbs. [1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |